Associated tags: Linden Lab, Publishing, Biotechnology, Pharmaceutical, Health, Head, Launch, Johns Hopkins School of Medicine, AbbVie, Thakeham, Senior advisor, Pharmaceutical industry, Forte, Pharmaceutical Development and Technology, COVID-19, Security (finance), Failure, Research, Terra Venture Partners, Degenerative disease, General Health, R
Locations: SAN FRANCISCO, UNITY
Retrieved on:
Monday, November 14, 2022
Biotechnology,
Pharmaceutical,
Health,
Head,
AbbVie,
Launch,
Failure,
Johns Hopkins School of Medicine,
Thakeham,
Senior advisor,
Security (finance),
Forte,
COVID-19,
Norwest Venture Partners,
Risk,
Pharmaceutical industry Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D.
Key Points:
- Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D.
- has been appointed to the Forte Biosciences Board of Directors.
- We are all excited to work with Scott to help drive long term value for Forte, said Fortes chairman and CEO Paul Wagner, Ph.D.
- Forte Biosciences, Inc. is a biopharmaceutical company and the lead product, FB-102, is a proprietary molecule with potentially broad autoimmune applications.
Retrieved on:
Monday, November 14, 2022
Biotechnology,
General Health,
Pharmaceutical,
Health,
Head,
Wind,
R,
Launch,
Johns Hopkins School of Medicine,
AbbVie,
Thakeham,
Research,
Senior advisor,
Degenerative disease,
Forte,
Terra Venture Partners,
Pharmaceutical Development and Technology,
Pharmaceutical industry Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update.
Key Points:
- Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update.
- Beyond FB-102, the Forte team continues to explore additional opportunities for pipeline development to drive long-term value creation.
- Forte ended the third quarter of 2022 with approximately $44.0 million in cash and cash equivalents.
- Forte had approximately 21.0 million shares of common stock outstanding as of September 30, 2022.
Retrieved on:
Thursday, September 5, 2019
Forte offers a fully integrated suite of solutions for clinical trial management, clinical data management,and research administration, including OnCore, Forte's flagship enterprise CTMS.
Key Points:
- Forte offers a fully integrated suite of solutions for clinical trial management, clinical data management,and research administration, including OnCore, Forte's flagship enterprise CTMS.
- "Forte is known across the research community as the gold standard for eClinical technology solutions," said Pat Donnelly, CEO of Advarra.
- "Joining Advarra is a great win for the research community and provides an outstanding platform for an interconnected clinical research ecosystem.
- Twice a year at the Onsemble Conference, clinical research professionals meet in person and discuss the latest challenges and solutions in clinical research.
These additional eReg capabilities also serve as the foundation for the regulatory component of Forte's Trial Data Exchange, an open, secure collaboration and data sharing platform feature that gives sites and sponsors the ability to collaborate seamlessly, share trial-specific data on demand, and structure necessary controls easily for access to regulatory, operational and clinical source data.
Key Points:
- These additional eReg capabilities also serve as the foundation for the regulatory component of Forte's Trial Data Exchange, an open, secure collaboration and data sharing platform feature that gives sites and sponsors the ability to collaborate seamlessly, share trial-specific data on demand, and structure necessary controls easily for access to regulatory, operational and clinical source data.
- Developed in concert with leading academic research organizations and eReg users like Yale, The Ohio State University, and Karmanos Cancer Institute, eReg now offers unique multi-site trial management capabilities that will enable industry-wide research collaboration.
- Forte eReg customers are able to track and manage their investigator-initiated trials and streamline workflows across individual research sites more cohesively.
- Customers will now be able to maximize compliance, data security, and efficiency of their full portfolio of studies across all departments within an organization and collaborate with sponsors on data and trial progress.
Comparative Analytics takes it a critical step further, by enabling sites and sponsors to engage in data-informed conversations based on site operational data from within the platform.
Key Points:
- Comparative Analytics takes it a critical step further, by enabling sites and sponsors to engage in data-informed conversations based on site operational data from within the platform.
- Pilot projects are already underway at Yale, University of Nebraska Medical Center, Moffitt and University of Florida using Forte's Trial Data Exchange solution.
- Twice a year at the Onsemble Conference, clinical research professionals meet in person and discuss the latest challenges and solutions in clinical research.
- Forte provides all research professionals complimentary blog articles, eBooks, webinars and more to support continuous learning on industry topics.
The fund will operate alongside Forte's platform technologies and include open-source solutions designed in collaboration with Ripple to accelerate the mainstream adoption of blockchain technology in gaming.
Key Points:
- The fund will operate alongside Forte's platform technologies and include open-source solutions designed in collaboration with Ripple to accelerate the mainstream adoption of blockchain technology in gaming.
- By focusing on cross-chain interoperability out of the gate, Forte is setting the foundation for long-term, sustained consumer adoption of blockchain technology.
- The Forte team is comprised of game industry veterans that have built top grossing games globally and developed cutting edge game technology platforms.
- Headquartered in San Francisco, Forte is developing blockchain technology platforms and products built for the games industry.
Retrieved on:
Thursday, February 21, 2019
Forte is creating a platform offering for game developers to accelerate adoption of blockchain technologies supporting peer-to-peer economies within new and existing games.
Key Points:
- Forte is creating a platform offering for game developers to accelerate adoption of blockchain technologies supporting peer-to-peer economies within new and existing games.
- The Forte team previously helped create multiple leading technology platforms for the game industry and authored games played by hundreds of millions of people worldwide.
- Forte's mission is to accelerate the adoption of blockchain technology in the games industry by creating a host of decentralized products and solutions.
- By tackling hard technology problems behind the scenes, Forte is forging a more collaborative future between game developers, players and creators.
